knowledge -WSS

knowledge

author：comprehensive 2025-10-02 14:39:10 - browse：58

A crowd of miniature figurines facing towards an hourglass. -- cancer coverage from STAT — Adobe

It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.

There’s been a proliferation of various biological aging clocks, mathematical models that look at things like genetic markers or proteins in your body to make some estimation of an individual’s biological age. Research interest in using these clocks has exploded. In the last five years, thousands of papers on or incorporating the clocks have been published. The paper describing one popular biological aging clock, PhenoAge, has over 1,800 citations alone. One recent study suggested that a reason cancer incidence is increasing among younger adults may be accelerated aging, based on this particular clock.

But as scientists use these clocks to associate biological age with specific health risks, like cancer or dementia, and numerous companies eagerly offer biological age measurements in exchange for hundreds of bucks, it may be worth noting that experts don’t agree on what “biological age” actually is.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Readout Newsletter: CAR

When a patient nears the end, a feared therapy can comfort

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Dementia risk linked to living in disadvantaged areas: Study

EPA limits use of carcinogenic gas for sterilizing medical devices

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Virginia high school admissions case could be legal follow

Delta passengers in Vegas fall sick while waiting on flight in triple

Medical records are filled with copy

Ebola: Gilead Sciences antiviral shows promise as new treatment

The cancer drug shortage isn’t new — and neither are the solutions

In rare move, senator releases unverified FBI source report alleging Biden bribe

BioMarin wins approval for gene therapy to treat hemophilia A

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Medicare proposal to cover medical devices draws a mixed reaction

EPA limits use of carcinogenic gas for sterilizing medical devices

explore

Extensive review finds private equity owners jack up cost of care

A new ‘biological computer' targets cancer while sparing healthy cells

Readout Newsletter: CAR

Stanford president’s abrupt resignation sparks debate

Boston's new lab space is opening empty

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

focus

knowledge

focus

focus